N/A
Completed N=3,011
Evaluation of Desloratadine When Used in Patients With Either Allergic Rhinitis or Chronic Idiopathic Urticaria
Rhinitis · Urticaria
Source: ClinicalTrials.gov NCT00724698 ↗
Enrolled (actual)
3,011
Serious AEs
—
Results posted
Jul 2009
Primary outcomePrimary: Adverse Events — 41; 15; 1 adverse events reported
Summary
Eligible patients will be prescribed Desloratadine 1 tablet of 5 mg once daily. Patients will be asked to follow-up for a final visit after 14 days (Day 15) where the safety, tolerability and clinical efficacy will be measured.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Adverse Events |
41; 15; 1 | — |
Eligibility Criteria
Inclusion Criteria
- Outpatient men or women, age 12 years and above.
- Diagnosis of Allergic Rhinitis or Chronic Idiopathic Urticaria
Exclusion Criteria
- Known hypersensitivity to Desloratadine.
- Pregnancy or lactation
Data sourced from ClinicalTrials.gov (NCT00724698). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.